Main menu button

News

Research update Biosergen: Continued success in India and cash injection
07 Mar 2025
Research update Biosergen: Continued success in India and cash injection
Equity Research Biosergen
Carlsquare Equity Research interview with Biosergen
11 Feb 2025
Carlsquare Equity Research interview with Biosergen
Equity Research Biosergen
Research update Biosergen: Promising interim data as BSG005 saves lives
14 Nov 2024
Research update Biosergen: Promising interim data as BSG005 saves lives
Equity Research Biosergen
Carlsquare Equity Research interview with Biosergen
23 Sep 2024
Carlsquare Equity Research interview with Biosergen
Equity Research Biosergen
Research update Biosergen: First patient treated in phase Ib study a success
12 Sep 2024
Research update Biosergen: First patient treated in phase Ib study a success
Equity Research Biosergen
Research update Biosergen: Taking the next clinical step
05 Jul 2024
Research update Biosergen: Taking the next clinical step
Equity Research Biosergen
Equity Research Biosergen: Study permission received, BSG005 ready for testing in patients
11 Jun 2024
Equity Research Biosergen: Study permission received, BSG005 ready for testing in patients
Equity Research Biosergen
Research update Biosergen: Rights issue to fund crucial step for lead project
13 Mar 2024
Research update Biosergen: Rights issue to fund crucial step for lead project
Equity Research Biosergen
Carlsquare Equity Research interview with Biosergen
07 Mar 2024
Carlsquare Equity Research interview with Biosergen
Equity Research Biosergen
Equity research Biosergen: Rights issue to fund the next clinical step
02 Feb 2024
Equity research Biosergen: Rights issue to fund the next clinical step
Equity Research Biosergen
Research Update Biosergen: Licensing deal with Alkem and CTA submission
16 Jan 2024
Research Update Biosergen: Licensing deal with Alkem and CTA submission
Equity Research Biosergen
Research Update Biosergen, Q2 2023: Stable in costs but delays in clinical timeline
16 Aug 2023
Research Update Biosergen, Q2 2023: Stable in costs but delays in clinical timeline
Equity Research Biosergen
Equity research Biosergen: Plans for speedy development of lead candidate
29 Mar 2023
Equity research Biosergen: Plans for speedy development of lead candidate
Equity Research Biosergen
Initiation of coverage, Biosergen: Make antifungals great again
20 Mar 2023
Initiation of coverage, Biosergen: Make antifungals great again
Equity Research Biosergen